Pegcetacoplan (APL-2), a C3 and C3b inhibitor, has been evaluated in a phase II clinical trial as a treatment option for IgAN, lupus nephritis, primary membranous nephropathy (MN), and C3 glomerulopathy (ClinicalTrials.gov Identifier: NCT03453619), however, no data are available at this time. This evidence concerns the gene C3 and complement 3 glomerulopathy.